IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD

NAUnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2014

Conditions
Polypoidal Chorodial VasculopathyAge Related Macular Degeneration
Interventions
RADIATION

Iray

The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.

Trial Locations (1)

Unknown

Università Vita-Salute Istituto Scientifico San Raffaele, Milan

Sponsors
All Listed Sponsors
lead

Oraya Therapeutics, Inc.

INDUSTRY